Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
Inventors
Assignees
Publication Number
US-9919034-B2
Publication Date
2018-03-20
Expiration Date
2034-03-28
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against rabies, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), influenza, Ebola virus, Chikungunya virus, Venezuelan equine encephalitis, canine parvovirus, adenovirus-2, respiratory syncytial virus, rhinovirus-14, and vaccinia are disclosed.
Core Innovation
The invention provides methods for treating and prophylactically preventing viral infections in mammalian patients through systemic administration of ranpirnase or three other ribonucleases that are highly homologous to ranpirnase and share similar antiviral activities. Ranpirnase exhibits surprisingly broad-spectrum antiviral effects against a large number of viruses, including rabies, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), influenza, Ebola virus (EBOV), Chikungunya virus (CHIV), Venezuelan equine encephalitis virus (VEEV), canine parvovirus, adenovirus-2 (AV), respiratory syncytial virus (RSV), rhinovirus-14 (RV), and vaccinia.
The problem addressed by the invention is that while various drugs, including ranpirnase, have been proposed as antiviral agents, their demonstrated activities had been limited to only one or a few specific viruses. This invention reveals and substantiates that ranpirnase has unexpectedly strong antiviral effects against a diverse array of viruses, even those that are highly resistant to treatment.
The broad-spectrum antiviral effect of ranpirnase is believed to arise from its RNA-degrading mechanisms, including degradation of transfer RNA (tRNA), viral double-stranded RNA, and microRNA or siRNA. By degrading these RNA species, ranpirnase can prevent viral replication processes. Importantly, ranpirnase's degradation of tRNA occurs with limited harm to normal mammalian cells due to their natural tRNA turnover, enabling systemic administration to reduce or eliminate viral infections without killing host cells. Moreover, similar ribonucleases highly homologous to ranpirnase are believed to have equivalent antiviral activity.
Claims Coverage
The patent contains ten claims, including six independent claims defining methods of treating or prophylactically protecting mammalian patients using ranpirnase against various viral infections classified within Baltimore Classification Group V and specific viral diseases.
Systemic administration of ranpirnase for treating viral infections in Baltimore Group V
A method of treating a viral infection in a mammalian patient, where the virus is classified in Baltimore Classification Group V, comprising systemically administering a therapeutically effective dose of ranpirnase.
Systemic administration of ranpirnase for treating rabies infection
A method of treating rabies infection in a mammalian patient by systemically administering a therapeutically effective dose of ranpirnase.
Systemic administration of ranpirnase for prophylactic protection against multiple viruses
A method of prophylactically protecting a mammalian patient from rabies, influenza, respiratory syncytial virus, or Ebola virus by systemically administering a therapeutically effective dose of ranpirnase.
Systemic administration of ranpirnase for treating Ebola virus infection
A method of treating Ebola virus infection in a mammalian patient by systemically administering a therapeutically effective dose of ranpirnase.
Systemic administration of ranpirnase for treating respiratory syncytial virus infection
A method of treating respiratory syncytial virus infection in a mammalian patient by systemically administering a therapeutically effective dose of ranpirnase.
Systemic administration of ranpirnase for prophylactic protection against Baltimore Group V viruses
A method of prophylactically protecting a mammalian patient from a viral infection classified in Baltimore Classification Group V by systemically administering a therapeutically effective dose of ranpirnase.
The claims define methods of systemic administration of ranpirnase to treat or prophylactically protect mammalian patients, particularly humans, from infections caused by viruses classified in Baltimore Group V and specific viruses such as rabies, Ebola, influenza, and respiratory syncytial virus.
Stated Advantages
Ranpirnase demonstrates surprisingly strong antiviral effects against a broad spectrum of viruses, including those highly resistant to treatment.
It can be used both therapeutically and prophylactically to treat or prevent viral infections.
Systemic administration of ranpirnase effectively inhibits viral replication without causing significant harm to normal mammalian cells.
Ranpirnase’s broad-spectrum RNA-degrading mechanisms enable its activity against diverse viruses, making it potentially effective against multiple viruses within Baltimore Classification Group V.
Other ribonucleases highly homologous to ranpirnase are expected to have similar antiviral activities.
Documented Applications
Therapeutic treatment of viral infections in mammals, including humans, by systemic administration of ranpirnase.
Prophylactic protection of mammals against infections from viruses such as rabies, MERS-CoV, influenza, Ebola virus, Chikungunya virus, Venezuelan equine encephalitis, canine parvovirus, adenovirus-2, respiratory syncytial virus, rhinovirus-14, and vaccinia.
Use of ranpirnase to protect or treat infections caused by viruses classified in Baltimore Classification Group V.
Treatment and protection against specific viral infections including rabies, Ebola virus, respiratory syncytial virus, influenza, and vaccinia virus.
Administration routes for ranpirnase include parenteral and enteral methods such as intravenous, intramuscular, oral, rectal, or aerosol delivery.
Interested in licensing this patent?